MUMBAI, April 20 (Reuters) - Japan's Daiichi Sankyo Company Ltd is selling shares worth up to $3.6 billion in Indian drugmaker Sun Pharmaceutical Industries Ltd, setting it on course to retreat from India after a rollercoaster 7 years.
Daiichi bought India's Ranbaxy Laboratories Ltd in 2008, betting on growing global demand for generic drugs, but found itself saddled with a company battling complaints and sanctions from the U.S. Food and Drug Administration (FDA).
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle19
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff17
14:45 Spain raises taxes to try to meet EU deficit target15
13:37 GoPro to cut about 15 percent of workforce14